Key result
Antiplatelet therapy linked to ~44% lower five-year stroke recurrence in patients with prior hemorrhagic stroke.
Why the study?
The risk factors for recurrence of hemorrhagic or ischemic stroke in patients with intracranial hemorrhage are inconclusive.
Does antiplatelet therapy reduce stroke recurrence in patients with a history of hemorrhagic stroke?
Cohort (n=6,180)
Does antiplatelet therapy reduce stroke recurrence in patients with a history of hemorrhagic stroke?
Age, hypertension, atrial fibrillation, cardiovascular disease, and prior ischemic stroke are risk factors for stroke recurrence in ICH patients, while antiplatelet therapy may be associated with a reduced risk of recurrence.
Risk factors for recurrent stroke after ICH remain inconclusive; leaves open need for prospective validation before informing secondary prevention.
BackgroundThe risk factors for recurrence of hemorrhagic or ischemic stroke in patients with intracranial hemorrhage (ICH) are inconclusive. This study was designed to investigate the risk factors for stroke recurrence in patients with ICH. MethodsThis population-based case-cohort study analyzed the data obtained from a randomized sample of 2 million subjects in the Taiwan National Health Insurance Research Database. The survival of patients with hemorrhagic stroke from January 1, 2000 to December 31, 2013 was included in the study. ResultsDuring the 5-year follow-up period, the recurrence rate of stroke was 12.2% (6.88% hemorrhagic stroke, 5.24% ischemic stroke). The recurrence rate of stroke was 14.2% in the without antiplatelet group and 7.9% in the antiplatelet group. The risk factors for hemorrhagic stroke were age (odds ratio [OR], 2.48), hypertension (OR: 2.24), atrial fibrillation (OR: 1.87), cardiovascular disease (OR: 1.41), and ischemic stroke history (OR: 1.56). The risk factors for ischemic stroke were age (OR: 2.57), hypertension (OR: 2.23), atrial fibrillation (OR: 1.87), cardiovascular disease (OR: 1.42), and ischemic stroke history (OR: 1.6). ConclusionThe risk factors of stroke recurrence were age, hypertension, atrial fibrillation, cardiovascular disease, and ischemic stroke history. Antiplatelet therapy may help prevent the recurrence of stroke.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2022) conducted a cohort in Hemorrhagic stroke (n=6,180). Antiplatelet therapy vs. Without antiplatelet therapy was evaluated on New-onset hemorrhagic or ischemic stroke. In patients with a history of hemorrhagic stroke, antiplatelet therapy was associated with a lower 5-year rate of stroke recurrence (7.9%) compared to no antiplatelet therapy (14.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: